SLNO — Soleno Therapeutics Inc · P/E 27, rev $94.6M

Soleno Therapeutics Inc (SLNO) is a biotechnology company listed on NASDAQ.

Latest reported SLNO revenue for 2026-03-31 was $94.6M. Net income was $31.4M. Revenue was up 43.3% from 2025-09-30 to 2026-03-31. SLNO currently screens at market cap $2.76B and trailing P/E 27.5.

Use this SLNO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLNO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLNO SEC filings page. Lician reads the product cache first so this HTML stays unique to Soleno Therapeutics Inc even when a live quote feed is slow.

Soleno Therapeutics Inc latest statements (FY2025)

Latest cached year on this hub. Full SLNO income, balance, and cash tables.

  • Revenue$190.4M
  • Net Income$20.9M
  • Total Assets$563.8M
  • Total Debt$0
  • Free Cash Flow$46.7M

SLNO recent filings